BioSpace News Archive

Apyx Medical Corporation today reported financial results for its fourth quarter and full year ended December 31, 2021, and introduced financial expectations for the full year ending December 31, 2022.

ZAP Surgical Systems, Inc. today announced that Unicancer , a leading academic promoter of oncology clinical trials and medical equipment purchasing health cooperation group for 19 French comprehensive cancer centers, has selected the ZAP-X ® Gyroscopic Radiosurgery ® platform for cranial stereotactic radiosurgery.

InflaRx N.V. today reported that the Company has received a corrected advice letter from the U.S. Food and Drug Administration (FDA) related to its Phase III program with vilobelimab for the treatment of hidradenitis suppurativa (HS).

Gennao Bio today announced the appointments of Peter Thompson, M.D., and Bradley Campbell to its Board of Directors.

Alnylam Pharmaceuticals, Inc. announced today that it has separately filed suit in United States District Court for the District of Delaware against Pfizer, Inc. and Moderna, Inc., seeking damages for infringement of U.S. Patent No. 11,246,933 (the “’933 Patent”) in the parties’ manufacture and sale of their messenger RNA (mRNA) COVID-19 vaccines.

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the upcoming oral presentation of the discovery and initial clinical utility of a novel signature that identifies patients with head and neck squamous cell carcinoma (HNSCC) that may benefit from treatment beyond typical surgical resection.

Led by Kizoo Technology Capital, the Seed round will be used to advance Revel Pharmaceuticals’ enzyme therapy pipeline towards the clinic.

Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022, at 4:30 p.m. ET to report its fourth quarter and full-year 2021 financial results and provide an update on its business and pipeline.

CytomX Therapeutics, Inc. today announced that preclinical data supporting the ongoing development of its conditionally activated cytokine program will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Ring Therapeutics today announced the appointments of Francois Nader, MD, MBA, David Epstein, MBA, and B. Lynne Parshall, Esq., to its Board of Directors.